The NDDD team has developed a pipeline of highly differentiated and innovative new chemical entities in focused therapeutic areas of Oncology, Immunology and Metabolic Disorders.

CURRENT CLINICAL PROGRAMS:

Endocrine:

The clinical Phase-I study successfully completed in Europe and the product was found to be safe and well tolerated. Phase-II study has been initiated in India in chronic kidney disease patients on dialysis and also not-on-dialysis.

Oncology:

Clinical Phase-I study has been successfully completed in Europe on terminally-ill patients (Lung Cancer, Melanoma & Colon Cancer). Phase-II study has commenced in India for treating a refractory type of Lung cancer which has RAS mutations for which no treatment exists worldwide.